Cardiovascular Risk and MASLD – Integrating Lipid Management with Novel Agents
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on X:
“Understanding MASLD, from molecular pathogenesis to cardiovascular risk.
A concise review for the clinical cardiologist.
MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia. Increased VLDL, small dense LDL, dysfunctional HDL.
The review in ATH journal highlights that.
•Statins are both safe and effective in MASLD, yet underprescribed.
•Ezetimibe and pemafibrate may improve lipid profile and hepatic parameters.
•GLP-1RAs and SGLT2i show dual benefit on liver fat, cardiometabolic risk, and CVD outcomes.
•Emerging agents (resmetirom, lanifibranor) target both hepatic fibrosis and lipid metabolism.
Lipid-lowering therapy remains central in MASLD management, but must be integrated with newer agents for optimal cardio-hepatic protection .”
Read more here.
Stay informed with Hemostasis Today.
-
May 27, 2026, 14:06Augustina Isioma Ikusemoro: Why Routine Platelet Transfusion Is Not Always Recommended in Dengue
-
May 27, 2026, 13:56Suzan Osman: The Major Types of Intracranial Hemorrhage in Clinical Practice
-
May 27, 2026, 13:55Raimundo C. Santos: The Main Aggressors of the Aorta and What These Lead to
-
May 27, 2026, 13:54Pooja Choradia: 2026 Acute Pulmonary Embolism Clinical Guidelines
-
May 27, 2026, 13:53Rehab Hussein: Blood Bank Training and the Clinical Responsibility of Preserving Human Life
-
May 27, 2026, 13:42New EAS Consensus Highlights Advances in Pediatric FH Care
-
May 27, 2026, 13:10Amos Gitonga Mbaabu: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion